Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 22, 2016

Evaluation of the hypochromic erythrocyte and reticulocyte hemoglobin content provided by the Sysmex XE-5000 analyzer in diagnosis of iron deficiency erythropoiesis

  • Mauro Buttarello EMAIL logo , Rachele Pajola , Enrica Novello , Giacomo Mezzapelle and Mario Plebani ORCID logo

Abstract

Background:

Iron deficiency represents the most frequent cause of anemia. To diagnose iron deficiency some biochemical tests such as serum ferritin and the transferring saturation percent (TSAT%) are usually used. Recently, some hematological parameters such as mean reticulocyte hemoglobin content (CHr or Ret-He) and percentage of hypochromic RBCs (Hypo% or %Hypo-He) were proposed as alternative to biochemical tests. In this study, the analytic performance and the diagnostic efficiency of these two parameters provided by Sysmex XE5000 analyzer on iron deficiency patients with or without anemia (IDA and ID, respectively) were evaluated.

Methods:

One hundred and sixty-four healthy adults, 58 with IDA, 21 with iron depleted stores (ID), 23 with β-thalassemia trait, and 24 with non iron deficiency anemia were selected. The gold standard used to define iron deficiency was the coexistence of serum ferritin below 15 μg/L (12 in women) and TSAT <16%.

Results:

For %Hypo-He, the best cut-off value for both IDA and ID is 0.9% while for Ret-He is 30.6 pg. For both parameters the performance was better to diagnose IDA (AUC, 0.96 and 0.98) than ID (AUC, 0.93 and 0.95). The Ret-He behavior was always slightly better than that of %Hypo-He.

Conclusions:

The use of these two parameters is useful to detect iron deficiency conditions if the hemoglobin synthesis has already been compromised.


Corresponding author: Mauro Buttarello, MD, Clinical Pathology Laboratory, Hospital of Adria, Piazza degli Etruschi, 45011, Adria (RO), Italy

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. De Maeyer E, Adiels-Teyman M. The prevalence of anemia in the world. World Health Stat Q 1985;38:303–16.Search in Google Scholar

2. Cook JD, Skikne BS. Iron deficiency: definition and diagnosis. J Intern Med 1989;226:349–55.10.1111/j.1365-2796.1989.tb01408.xSearch in Google Scholar PubMed

3. Thomas DW, Hinclhiffe RF, Briggs C, MC Dougall IC, Littlewood T, Cavill I. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013;161:639–48.10.1111/bjh.12311Search in Google Scholar PubMed

4. Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ, et al. Plasma ferritin determination as a diagnostic tool. West J Med 1986;145:657–63.Search in Google Scholar

5. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. J Am Med Assoc 1997;277:973–6.10.1001/jama.1997.03540360041028Search in Google Scholar PubMed

6. Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1–ii47.10.1093/ndt/gfh1031Search in Google Scholar

7. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(suppl 3):s11–145.10.1053/j.ajkd.2006.03.011Search in Google Scholar PubMed

8. UK Renal Association. Clinical Practice Guidelines Module 2: complications. UK Renal Association 2007. Available at: www.renal.org/guidelines.Search in Google Scholar

9. Chung M, Chan JA, Moorthy D, Hadar N, Ratichek SJ, Concannon TW, et al. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease: future research needs. Agency for Health Care research and quality. Rockville, MD: US Department of Health and Human Services, 2013.Search in Google Scholar

10. Brugnara C. A haematological “gold standard” for iron-deficient states (editorials)? Clin Chem 2002;48:981–2.10.1093/clinchem/48.7.981Search in Google Scholar

11. MacDougall IC, Cavill I, Hulme B, Bain B, McGregor E, McKay P, et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. Br Med J 1992;304:225–6.10.1136/bmj.304.6821.225Search in Google Scholar PubMed PubMed Central

12. NICE. Anaemia management in people with chronic kidney disease. Clinical guideline 114. London: National Institute for Health and Clinical Excellence, 2011.Search in Google Scholar

13. Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001;16:1416–23.10.1093/ndt/16.7.1416Search in Google Scholar PubMed

14. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003;18:370–7.10.1093/ndt/18.2.370Search in Google Scholar PubMed

15. Bovy C, Gothot A, Delanaye P, Warling X, Krzesinski JM, Beguin Y. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity. Nephrol Dial Transplant 2007;22:1156–62.10.1093/ndt/gfl765Search in Google Scholar PubMed

16. Buttarello M, Pajola R, Novello E, Rebeschini M, Cantaro S, Oliosi F, et al. Diagnosis of iron deficiency in patients undergoing hemodialysis. Am J Clin Pathol 2010;133:949–54.10.1309/AJCPQAX0JFHFS0OASearch in Google Scholar PubMed

17. Franck S, Linssen J, Messinger M, Thomas L. Potential utility of Ret-Y in the diagnosis of iron- restricted erythropoiesis. Clin Chem 2004;50:1240–2.10.1373/clinchem.2004.030254Search in Google Scholar PubMed

18. Clinical and Laboratory Standards Institute (CLSI). Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline-third edition. Wayne, PA: C28-A3, 2008.Search in Google Scholar

19. Camaschella C. Iron-deficiency anemia. N Engl J Med 2015;372:1832–43.10.1056/NEJMra1401038Search in Google Scholar PubMed

20. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood 2006;107:1747–50.10.1182/blood-2005-07-3046Search in Google Scholar PubMed PubMed Central

21. Fishbane S, Kowalsky EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996;7:2654–7.10.1681/ASN.V7122654Search in Google Scholar PubMed

22. Urrechaga E, Borque L, Escanero JF. Potential utility of the new Sysmex XE 5000 red blood cell extended parameters in the study of disorders of iron metabolism. Clin Chem Lab Med 2009;47:1411–6.10.1515/CCLM.2009.301Search in Google Scholar PubMed

23. Urrechaga E, Borque L, Escanero JF. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Int J Lab Hem 2013;35:144–9.10.1111/ijlh.12013Search in Google Scholar PubMed

24. Noronha JF, Grotto HZ. Measurement of reticulocyte and red blood cell indices in patients with iron deficiency anemia and β-thalassemia. Clin Chem Lab Med 2005;43:195–7.10.1515/CCLM.2005.033Search in Google Scholar PubMed

25. Thomas C, Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002;48:1066–76.10.1093/clinchem/48.7.1066Search in Google Scholar

26. Katodritou E, Terpos E, Zervas K, Speletas M, Kapetanos D, Kartsios C, et al. Hypochromic erythrocytes(%): a reliable marker for recognozing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 2007;86:369–76.10.1007/s00277-007-0258-xSearch in Google Scholar PubMed

27. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret-He) and assessment of iron-deficient states. Clin Lab Haematol 2006;28:303–8.10.1111/j.1365-2257.2006.00812.xSearch in Google Scholar PubMed PubMed Central

28. Garzia M, Di Mario A, Ferraro E, Tazza L, Rossi E, Luciani G, et al. Reticulocyte haemoglobin equivalent; an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy. Lab Hematol 2007;13:6–11.10.1532/LH96.06037Search in Google Scholar PubMed

29. Maconi M, Cavalca L, Danise P, Cardarelli F, Brini M. Erythrocyte and reticulocyte indices in iron deficiency in chronic kidney disease: comparison of two methods. Scand J Clin Lab Invest 2009;69:365–70.10.1080/00365510802657673Search in Google Scholar PubMed

Received: 2016-1-17
Accepted: 2016-4-25
Published Online: 2016-9-22
Published in Print: 2016-12-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 8.12.2023 from https://www.degruyter.com/document/doi/10.1515/cclm-2016-0041/html
Scroll to top button